logo

NEPHROPLUS vs PAR: Stock Comparison

NEPHROCARE HEALTH SERV L vs PARUpdated 19 Oct 26, 4:08 PM ISTNSE & company filings

NEPHROCARE HEALTH SERV L is the larger company by market capitalisation. NEPHROCARE HEALTH SERV L shows faster revenue growth, while PAR shows a lower P/E, a higher ROE and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

NEPHROPLUS leads 2; PAR leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

NEPHROPLUSPAR

Valuation lens

What price are you paying?

Market CapContext only
₹6,124 Cr
₹130 Cr
P/E RatioPAR has the lower reading
79.5x
8.55x ✓
P/B RatioPAR has the lower reading
5.47x
0x ✓
EPSPAR has the higher reading
₹3.19
₹3.83 ✓
Book ValueContext only
₹111.27
₹91.01
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
NEPHROPLUS is the larger company
₹6,124 Cr vs ₹130 Cr
P/E Ratio
PAR has a lower P/E
8.55x vs 79.5x
P/B Ratio
PAR has a lower P/B
0x vs 5.47x
EPS
PAR has higher earnings per share
₹3.83 vs ₹3.19
Revenue Growth (TTM YoY)
NEPHROPLUS has faster revenue growth
0% vs -12.2%
EPS Growth (TTM YoY)
NEPHROPLUS has faster EPS growth
0% vs -48.5%
ROE
PAR has a higher ROE
11.71% vs -0.83%
ROCE
PAR has a higher ROCE
24.85% vs 5.17%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricNEPHROPLUSPAR
Sector—Healthcare
Industry—Pharmaceuticals

Price

MetricNEPHROPLUSPAR
Live Price₹611.55₹164.95
Day Change-0.46%-1.96%
Volume1.53 L7.26 L
52-Week High₹781.5₹180
52-Week Low₹446₹78.05
Distance from 52W High-21.75%-8.36%

Valuation

MetricNEPHROPLUSPAR
Market Cap₹6,124 Cr₹130 Cr
P/E Ratio79.5x8.55x
P/B Ratio5.47x0x
EPS₹3.19₹3.83
Book Value₹111.27₹91.01
Dividend Yield0%0%

Growth

MetricNEPHROPLUSPAR
Revenue Growth (TTM YoY)0%-12.2%
EPS Growth (TTM YoY)0%-48.5%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricNEPHROPLUSPAR
ROE-0.83%11.71%
ROCE5.17%24.85%
Net Margin7.69%12.65%
Operating Margin7.3%16.81%
Debt to Equity0.01x0x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricNEPHROPLUSPAR
Promoter Holding18.79%▼ 2.28 pp73.41%
FII Holding11.73%▲ 2.95 pp0%
DII Holding8.11%▼ 0.94 pp0.09%
Public Holding21.85%▲ 3.53 pp26.51%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: NEPHROCARE HEALTH SERV L and PAR.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.